ASM Microbe 2018–connecting scientists with their science–showcases the best microbial sciences in the world, and provides a one-of-a-kind forum to explore the complete spectrum of microbiology from basic science to translation and application. Eight tracks allow you to narrow in on your scientific niche, and connect with the experts in your field.
Innovative Solutions for Automated Imaging
Since 1986, MetaSystems has been developing and manufacturing systems for automated microscope based imaging. Our close communication and relationships with our customers have been an essential part of the MetaSystems philosophy; the last 30 years have proven that this is a successful strategy. From humble beginnings, MetaSystems has grown into a leading solutions provider while still being connected to our roots as an independent, employee-owned, innovation-driven company.
MetaSystems’ latest innovation, Neon, is a dynamic, modern imaging platform which reliably manages cases, images, and results from single workstation environments to large multi-user, multi-site installations. The Neon imaging platform ensures that all relevant information is accessible whenever needed.
To learn more about our innovative laboratory solutions, we recommend beginning on the application pages. If you are already familiar with our product portfolio, you may proceed directly to the pages covering your product of interest. If you are unable to find what you are looking for, please do not hesitate to contact the MetaSystems partner in your region for assistance.
Are You Looking for Probes?
MetaSystems Probes now has its own website. If you are looking for MetaSystems XCyting DNA Probes, please visit the MetaSystems Probes website.
Detection of circulating endothelial and tumor cells
Non-hematopoietic circulating rare cells (CRCs) mainly consist of circulating tumor cells (CTCs) and circulating endothelial cells (CECs). Clinical relevance of CECs in tumor angiogenesis1 and CTCs in tumor metastasis [...] have been substantially discussed elsewhere. [...] In the present report, we extended our previous prototyping study to significantly improve the unique strength of SE-iFISH, which was developed to combine in situ phenotypic identification of tumor biomarker and karyotypic characterization of chromosome ploidy in CRCs enriched from patient biofluids (blood, bone marrow, ascites, malignant pleural effusion, and cerebrospinal fluids, etc.) [...]. [...] Metafer-iFISH®, an automated CRC scanning and image analysis system, was recently co-developed by Carl Zeiss (Oberkochen, Germany), MetaSystems (Altlussheim, Germany) and Cytelligen (San Diego, CA, USA) [...]. High through-put X-Y-Z 3-dimensional slide scanning, image acquisition, processing, classification of CRC subtypes, and statistical analyses of each subcategory of the target cells could be fully automatically performed by Metafer-iFISH upon cell size, cell cluster, quantified chromosome ploidy, and immunofluorescence staining intensity of multi-tumor biomarkers expression displayed in diverse fluorescence channels, avoiding interference from human error or bias. [...] The novel SE-iFISH provides a unique strategy for expeditious and effective enrichment, in situ phenotypic as well as karyotypic co-detection of various non-hematopoietic CRCs in cancer patients or metastatic mouse model of patient derived xenograft (mPDX)33, which allows for classification of CTCs and CECs into diverse subtypes upon biomarker expression as well as chromosome ploidy, and each subtype of CRCs may correlate with distinct clinical outcome, such as tumor angiogenesis, cancer metastasis, relapse and therapeutic drug resistance [...].